Dicot demonstrates good results in new efficacy study
Press release: Uppsala, June 29, 2022. Dicot AB is developing a new potency drug aiming at becoming the first choice of treatment. The company announces today that the newly developed oral formulation demonstrates good results in a recently conducted efficacy study.An efficacy study conducted by the company's partner, the French research company Pelvipharm, in a validated animal model for erectile function, shows good results with the new oral formulation. The effect was shown on all studied parameters in the animals measured seven days after the last dose, and the effect is statistically